Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life

Gupta, Pratima; Sturdee, David W.; Palin, S. L.; Majumder, Kaberi; Fear, Rhona M.; Marshall, Tom; Paterson, Ian

doi:10.1080/13697130500487224

Cited by 190 publications

(171 citation statements)

References 36 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…However, the mechanism of venlafaxine's effects on hot flashes remains unclear. That a 50% or more decrease in physiological hot flashes was associated with improved secondary outcomes supports the existence of a symptom cluster or menopausal syndrome as proposed by others [5,[45][46][47]. Because secondary outcomes were linked to physiological hot flashes, these improvements are not an artifact of positive reporting bias.…”

Section: Discussionmentioning

confidence: 48%

See 1 more Smart Citation

Randomized, Double-Blind, Placebo-Controlled Crossover Trials of Venlafaxine for Hot Flashes After Breast Cancer

et al. 2007

View full text Add to dashboard Cite

LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Discuss the efficacy of venlafaxine in alleviating hot flashes and improving secondary outcomes.2. Identify the week of treatment that venlafaxine was most effective.3. List three side effects associated with venlafaxine.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACT Background. Although venlafaxine reduces self-reported hot flashes, no data have established the drug's impact on physiologically documented hot flashes. Two randomized, double-blind, placebo-controlled crossover trials examined the efficacy of two doses of venlafaxine in relation to physiological and self-reported hot flashes and other outcomes, including negative affect, fatigue, sleep, and quality of life.Methods. Sample: 57 breast cancer survivors in the low-dose study; 20 in the high-dose study. Setting: university cancer clinics in the Southeast and Midwest. Intervention: 37.5 mg of venlafaxine (low-dose study) or 75 mg of venlafaxine (high-dose study). Measures: hot flash frequency (physiological monitor, diary, and event marker), hot flash severity (diary), hot flash bother (diary), and questionnaires for hot flash impact on daily life, negative affect, fatigue, sleep, and quality of life.

show abstract

Section: Discussionmentioning

confidence: 48%

“…Frequent, severe, and bothersome hot flashes are well documented in breast cancer survivors [1][2][3][4][5]. Approximately 65% of survivors experience hot flashes, with 59% rating the symptom as severe and 44% rating the symptom as extremely bothersome.…”

Section: Introductionmentioning

confidence: 99%

Randomized, Double-Blind, Placebo-Controlled Crossover Trials of Venlafaxine for Hot Flashes After Breast Cancer

et al. 2007

View full text Add to dashboard Cite

show abstract

“…), compared them against placebo or other SSRIs, and evaluated vasomotor symptoms (daily hot flash frequency or improvement in vasomotor scores). We specifically excluded studies that enrolled cancer patients and patients receiving selective estrogen receptor modulators (SERMs) because hot flashes and night sweats are common complaints (up to 80 %) of patients receiving tamoxifen for breast cancer, [14][15][16] women taking hormonal replacement therapy and patients with diagnoses of depression.…”

Section: Eligibility Criteriamentioning

confidence: 99%

“…16 SSRIs in these women may also speed the metabolism of tamoxifen to inactive metabolites, possibly reducing the severity of side effects, including hot flashes. 39 Therefore, our findings relate to women suffering from natural peri-and post-menopausal symptoms.…”

Section: Implications For Practice and Researchmentioning

confidence: 99%

SSRIs for Hot Flashes: A Systematic Review and Meta-Analysis of Randomized Trials

et al. 2013

View full text Add to dashboard Cite

BACKGROUND: Hot flashes are the most commonly reported vasomotor symptom during the peri-and early post-menopausal period. OBJECTIVES: To systematically review, appraise and summarize the evidence of the impact of different SSRIs on peri-menopausal hot flashes in healthy women in randomized, controlled trials. METHODS: A comprehensive literature search was conducted of MEDLINE™, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science and Scopus through March 2013. Two independent reviewers selected studies and extracted data. Random effects meta-analysis was used to pool outcomes across studies, and Bayesian mixed treatment methods were used to rank SSRIs in terms of effectiveness. RESULTS: We included a total of 11 randomized controlled trials with good methodological quality enrolling 2,069 menopausal and post-menopausal women (follow-up 1-9 months, mean age 36-76 years, mean time since menopause 2.3-6.6 years). Compared with placebo, SSRIs were associated with a statistically significant decrease in hot flash frequency (difference in means −0.93; 95 % CI −1.46 to −0.37; I 2 = 21 %) and severity assessed by various scales (standardized difference in means −0.34; 95 % CI −0.59 to −0.10; I 2 = 47 %). Adverse events did not differ from placebo. Mixed treatment comparison analysis demonstrated the superiority of escitalopram compared to other SSRIs in terms of efficacy. CONCLUSION: SSRI use is associated with modest improvement in the severity and frequency of hot flashes but can also be associated with the typical profile of SSRI adverse effects.

show abstract

“…In the Arimidex, Tamoxifen, Alone or in Combination trial, vaginal dryness was observed in 16.3% and dyspareunia was observed in 17.8% of anastrozole-treated patients, but in only 8.4% and 7.5% of tamoxifen-treated patients, respectively [2]. As AIs are used more frequently in the growing population of postmenopausal women with hormone receptor-positive breast cancer, this serious complication of therapy that dramatically affects quality of life will become more common [3].…”

Section: Introductionmentioning

confidence: 99%

Topical Testosterone for Breast Cancer Patients with Vaginal Atrophy Related to Aromatase Inhibitors: A Phase I/II Study

et al. 2011

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Evaluate early data regarding the impact of daily vaginal testosterone on estradiol and testosterone levels in breast cancer patients receiving treatment with aromatase inhibitors.2. Explain the potential clinical benefits of vaginal testosterone therapy to treat vaginal atrophy in women with breast cancer receiving long-term aromatase inhibitor therapy.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. ABSTRACT Breast CancerThe

show abstract

Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life

Cited by 190 publications

References 36 publications

Randomized, Double-Blind, Placebo-Controlled Crossover Trials of Venlafaxine for Hot Flashes After Breast Cancer

Randomized, Double-Blind, Placebo-Controlled Crossover Trials of Venlafaxine for Hot Flashes After Breast Cancer

SSRIs for Hot Flashes: A Systematic Review and Meta-Analysis of Randomized Trials

Topical Testosterone for Breast Cancer Patients with Vaginal Atrophy Related to Aromatase Inhibitors: A Phase I/II Study

Contact Info

Product

Resources

About